Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Gelmon, Karen AKaren AGelmonFasching, Peter APeter AFaschingCouch, Fergus JFergus JCouchBalmaña, JudithJudithBalmañaDelaloge, SuzetteSuzetteDelalogeLabidi-Galy, IntidharIntidharLabidi-GalyBennett, JamesJamesBennettCHIUN-SHENG HUANGet al.2022-04-152022-04-1520210959-8049https://scholars.lib.ntu.edu.tw/handle/123456789/604463In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a setting reflecting clinical practice.enBRCA1 gene; BRCA2 gene; Breast cancer; Effectiveness; Germline mutation; Metastatic; Olaparib; Progression-free survival; Treatment outcome[SDGs]SDG3Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysisjournal article10.1016/j.ejca.2021.03.029340875732-s2.0-85107637276WOS:000678059500008https://api.elsevier.com/content/abstract/scopus_id/85107637276